Recap: ThermoGenesis Holdings Q2 Earnings

Shares of ThermoGenesis Holdings THMO decreased 2.7% after the company reported Q2 results.

Quarterly Results

Earnings per share rose 62.75% over the past year to ($0.38), which missed the estimate of ($0.18).

Revenue of $2,201,000 declined by 1.83% year over year, which beat the estimate of $1,980,000.

Guidance

Earnings guidance hasn't been issued by the company for now.

Revenue guidance hasn't been issued by the company for now.

Details Of The Call

Date: Aug 12, 2021

Time: 04:30 PM

ET Webcast URL: https://78449.choruscall.com/dataconf/productusers/thmo/mediaframe/46146/indexr.html

Technicals

Company's 52-week high was at $6.39

Company's 52-week low was at $1.92

Price action over last quarter: Unaffected 0.00%

Company Overview

ThermoGenesis Holdings Inc develops, commercializes and markets a range of automated technologies for CAR-T and other cell-based therapies. The company currently markets a full suite of solutions for automated clinical biobanking, point-of-care applications, and automation for immuno-oncology, including its semi-automated, functionally-closed CAR-TXpress platform, which streamlines the manufacturing process for the emerging CAR-T immunotherapy market. It offers the AutoXpress and BioArchive platforms for automated clinical bio-banking, PXP platform for point-of-care cell-based therapies and CAR-TXpress platform for bio-manufacturing for immuno-oncology applications.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: EarningsBZI-Recaps
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!